NEW YORK, Oct. 20 /PRNewswire/ -- EmPower Research, LLC, a pioneer in the field of Business Research and Information Consulting, launched its first-ever study on the Indian Contract Research Organization (CRO) industry on Saturday.
The report titled 'Indian Contract Research Industry' (CRO-nicles) captures the industry's current position, trends, challenges and its outlook by speaking to the top line industry executives first hand.
India currently stands as one of the highest ranked emerging countries in global contract research in the pharmaceuticals industry followed by Italy and China, and is expected to grow by 20% compounded annual growth, over the next five years. Over 30 global top-ranking contract research organizations (CROs), including Quintiles and Kendle have set up centers in India.
Several major pharmaceutical companies are also setting up new centers, expanding their existing centers, or revisiting their India-centric strategies after a long time lapse. Today, as with every outsourced activity, clinical research has evolved as a major driver for the Indian CRO industry.
The key highlights of the report include an overview of the Indian clinical trials market, its size, and costs incurred, advantages and future outlook. The report examines the clinical trials market scenario, critical success factors driving the industry and key issues related to government regulations and governing clinical trials. In addition, the report also explores the outsourcing opportunities, industry dynamics and anticipated changes in the industry.
As part of the report, profiles of 27 major Indian CRO companies covering aspects like services offered, key people, clinical phases and financials for the last two years are also presented.
This report will be useful to Contract Research Organizations,
pharmaceutical companies, venture capitalists (VCs) and leveraged buyout
(LBO) firms, pharmaceutical educational institutions, research bo
|SOURCE EmPower Research, LLC|
Copyright©2007 PR Newswire.
All rights reserved